checkdown-arrowsearchshare

This site is intended for healthcare professionals outside the U.S.

The OTEZLA® International Website


close x

You are now leaving Otezla.net!


OTEZLA provides efficacy in biologic-naïve patients1*

Response was maintained with OTEZLA through
week 521†

 

SIGNIFICANTLY MORE PATIENTS ACHIEVED PASI-75 VS PLACEBO1,a,b

pasi‐75 improvement
a

LIBERATE® study. mITT, LOCF.

b

P < 0.0001, OTEZLA vs placebo.

*

In biologic-naïve patients with moderate to severe plaque psoriasis.

mITT, LOCF.

Sustained efficacy in biologic-naïve patients1,2*

OTEZLA improves skin severity in biologic-naïve patients, with response maintained up to 1 year1,2

 

SUSTAINED PASI IMPROVEMENT UP TO 1 YEAR1,2,a

pasi improvement from otezla
a

LIBERATE study. Data as observed among patients with a value at the time point indicated, with no imputation for missing values.

*

In biologic-naïve patients with moderate to severe plaque psoriasis.

LIBERATE, Evaluation in a Placebo-Controlled Study of Oral Apremilast and Etanercept in Plaque Psoriasis; LOCF, last observation carried forward; mITT, modified intent to treat; PASI, Psoriasis Area and Severity Index.

References: 1. Reich K, Gooderham M, Green L, et al. The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE). J Eur Acad Dermatol Venereol. 2016. 2. Reich K, Soung J, Gooderham M, et al. 52-Week Efficacy and Safety of Apremilast and Switch From Etanercept in Patients With Moderate to Severe Psoriasis: Results From the LIBERATE Study. Presented at: the Annual European Congress of Rheumatology EULAR 2016; 8–11 June 2016; London, UK.


Select an e-mail client to share

close x